Bridge Biotherapeutics’ history
What the future for Bridge Biotherapeutics holds
A few questions from the audience
Q: You have an impressive reach with Korea and Boston. What are your plans for Europe, Switzerland, and the Basel Area?
A: Our main goal is to become a fully integrated biotech company. We feel that Basel has exactly what we need to get there. The growing ecosystem based on innovative early-stage science as well as the world’s leading big pharma here enables innovation and growth for biotech companies in a manner that’s very unique globally.
Q: What traits have you observed in successful startups?
A: Successful biotech ecosystems have a few underlying similarities, such as a focus on science. Entrepreneurs are willing to take risks and invest in trial and error. They’re also very good at breaking mental barriers to creativity and collaboration.
Q: When it comes to partnering, what exactly is Bridge Biotherapeutics looking for in terms of collaboration?
A: We’re very open-minded and pursue new and innovative ideas no matter where they come from. A look at our pipeline shows that all our assets are first-in-class. We’re willing to do things that have not been done before. We encourage anyone who’s interested in working with us to get in touch.
Q: Do government investments into the life sciences ecosystem bring value, or are they not necessary, given that government officials may not be specialized in the field?
A: Although I empathize with the startup-led approach, government support is crucial. Government can help set long-term vision. Government initiatives can provide important initial funding for projects or ventures that are often too early or too risky, even for venture capital investors. Sometimes government money can be the least risk-averse.